DivestmentJun 15, 2026, 04:11 PM
Adaptive Biotechnologies to Separate MRD & Immune Medicine Businesses
AI Summary
Adaptive Biotechnologies Corporation announced its intention to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. The company is evaluating strategic and structural alternatives for Immune Medicine to support its growth and value creation outside of Adaptive, expecting to identify a preferred path by year-end 2026. This move follows the establishment of both as separate operating segments in 2024, with MRD achieving significant scale and profitability, and Immune Medicine advancing its discovery platform.
Key Highlights
- Adaptive Biotechnologies intends to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.
- The company expects to identify its preferred path to separation by year-end 2026.
- MRD business revenue grew from $103 million in 2023 to $212 million in 2025.
- MRD business reported $15 million in 2025 adjusted EBITDA.
- MRD's clonoSEQ platform covers over 300 million lives and is used in over 180 active biopharma trials.
- Immune Medicine has over 6 million functional T-cell receptor (TCR)-antigen pairs.
- Immune Medicine has well-characterized data sets on more than 10,000 patients.
Price Impact
More from ADPT